Medical/Pharmaceuticals

DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it w...

2023-01-05 08:00 2034

Cognos Therapeutics, Inc. to Become Publicly Listed on Nasdaq via Business Combination with Nocturne Acquisition Corporation

* Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and str...

2023-01-05 07:10 4159

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...

2023-01-05 00:00 2556

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

* Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies * Synaffix to receive up to $150m in upfront and milestone payments plus royalties  SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused ...

2023-01-04 21:00 2485

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Study met all primary endpoints ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical the...

2023-01-04 20:30 2191

China's optimization of control measures lays solid foundation for COVID-19 response

BEIJING, Jan. 4, 2023 /PRNewswire/ -- A report from People's Daily: Local authorities and relevant departments inChina have been making unremitting efforts recently to ensure the supply of medical resources, satisfy the demand for medicines and focus on the prevention and treatment of high-risk g...

2023-01-04 15:39 2422

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 4, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr.Mingdong Zhang to the company's Scientific Advisory Board (SAB). Dr. Zhang will provide guidance on Pulnovo Medical's clinical development and registration strategya...

2023-01-04 10:46 2289

Bioniq® Repair Toothpaste with 20% BioHAP*, scientifically proven to remineralise enamel and keeps teeth healthy and strong

HONG KONG, Jan. 4, 2023 /PRNewswire/ -- While most Westerners prefer trimmed meat and fish fillets, a vast majority of Asian diners enjoy eating their food off bones, picking flesh from carcasses, and gnawing on tendons,cartilage, and bones for gooey, chewy textures1. Hong Kong, a food paradise ...

2023-01-04 10:00 3840

Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that TST003, its first...

2023-01-04 08:00 2602

Sisram Medical to Present Virtually at the 25th Annual Needham Growth Conference

CAESAREA, Israel, Jan. 3, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blo...

2023-01-03 21:30 1367

Call for Application for 2023 Tsinghua Amgen Scholars Program

BEIJING, Jan. 3, 2023 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...

2023-01-03 21:20 1334

Clarivate and the Chinese Academy of Sciences Release Annual Joint Report to Identify 165 Research Fronts

Selecting significant research specialties in sciences and social sciences LONDON, Jan. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, and theChinese Academy of Sciences (CAS) today released R...

2023-01-03 16:02 2043

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company

--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava inChina in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership ...

2023-01-03 16:00 3677

Bayer Taiwan Company Ltd. and Berocca Honored at the Asia Pacific Enterprise Awards 2022 Taiwan

SINGAPORE, Jan. 3, 2023 /PRNewswire/ -- The Asia Pacific Enterprise Awards (APEA) 2022 Taiwan is pleased to honor 34 outstanding business leaders and enterprises for their commendable dedication toward spearheadingTaiwan's economic recovery and development. Presented by leading regional NGO Enter...

2023-01-03 10:05 1611

CGTN: China monitors coronavirus mutations to adjust COVID-19 response

BEIJING, Jan. 3, 2023 /PRNewswire/ -- With China loosening its COVID-19 restrictions, some experts have expressed concern thatChina's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating. "It is a worry," said CNN, citing William Schaffner, professor at the Divisi...

2023-01-03 08:27 1866

CStone announces the registrational clinical trial of sugemalimab as first-line treatment in patients with esophageal squamous cell carcinoma met primary endpoints and plans to submit a supplemental NDA to NMPA

* Sugemalimab became the first anti-PD-L1 monoclonal antibody that achieved positive results in the study of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. * Sugemalimab in combination with chemotherapy demonstrated a statistically ...

2023-01-03 08:10 3622

Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints

HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") was recently informed that onDecember 29, 2022, Viking Therapeutics, Inc. ("Viking"), a pharmaceutical company inthe United States, filed certain complaints against Ascletis, its founder Dr. J...

2023-01-02 19:24 2743

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

GAITHERSBURG, Md., Dec. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CI...

2022-12-30 21:00 4161

Mentice AB (publ) receives an order of USD 540,000 for simulation solutions from Corewell Health, Grand Rapids, Michigan, USA

GOTHENBURG, Sweden, Dec. 30, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg , a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health,Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions...

2022-12-30 20:53 3397

Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19

* GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load;...

2022-12-30 13:23 3263
1 ... 139140141142143144145 ... 398